Cambridge Tests AI-Designed Universal Coronavirus Vaccine

The University of Cambridge and collaborators have completed a Phase 1 human trial of a vaccine whose active component was designed using artificial intelligence, per a Cambridge release and corroborating coverage from the BBC and Euronews. The trial, named pEVAC-PS, enrolled 39 healthy volunteers aged 18 to 50 at NIHR Clinical Research Facilities in Southampton and Cambridge and was sponsored by University Hospital Southampton NHS Foundation Trust. Investigators reported the DNA-based vaccine, delivered through a needle-free jet system, was safe with no significant side-effects and triggered immune responses to SARS-CoV-2, SARS, and related bat coronaviruses. The platform was developed with spin-out DIOSynVax (DVX) Ltd.

The approach compiles genetic sequences from diverse members of a viral family, then applies machine learning and computational protein design to generate a 'super-antigen' that captures conserved features across strains, aiming for broad protection (BBC; Euronews). Researchers describe this as the first time a vaccine's key active ingredient was designed entirely by computer simulation and tested in humans.

For applied ML in biology, the trial marks a milestone in translational computational design: an AI-generated antigen has reached human testing. Proponents argue that shifting from strain-specific to family-wide targets could reduce the need for frequent reformulation, but broader protective efficacy must still be established in larger trials with real-world challenge.

The Cambridge release quotes Professor Jonathan Heeney: 'We've converted vaccine development from being reactive to being future proof. Our vaccines will continue to provide protection against viruses even as they mutate into new strains.'

Phase 1 trials primarily assess safety and initial immune responses, not population-level effectiveness; current coverage does not provide randomized efficacy data or durability measures. Observers should watch for a planned Phase 2 study, peer-reviewed publication of protocol and immunogenicity data, independent replication in other virus families, and structural data confirming the designed antigen's stability and epitope presentation.